32 Triple-Negative Breast Cancer and Pathological Complete Response: A Study of Racial Disparities

Publication
Article
Miami Breast Cancer Conference® Abstracts Supplement38th Annual Miami Breast Cancer Conference® - Abstracts
Volume 35
Issue suppl 1
Pages: 45

Maithreyi Sarma, MBBS1; Samar Nasir, MD2; Ashwini Ronghe, MD2; Kristopher Atwood, PhD1; Medhavi Gupta, MBBS1; Amy Early, MD1; Tracey O’Connor, MD1; Ellis Levine, MD1; Shipra Gandhi, MD1

1Roswell Park Comprehensive Cancer Center, Buffalo, NY.

2State University of New York at Buffalo, School of Medicine & Biomedical Sciences, Buffalo, NY.

Background

Triple-negative breast cancer (TNBC), one of the more aggressive subtypes of breast cancer, is twice as frequent and associated with higher mortality in Non-Hispanic Black (NHB) women compared with non-Hispanic White (NHW) women. Factors contributing to this racial disparity have been shown to include socioeconomic status, insurance variables, delays in diagnosis/treatment, and comorbidities. We examined the association between race and clinical outcomes—pathological complete response (pCR), recurrence-free survival (RFS), and overall survival (OS)—in patients (pts) treated with neoadjuvant chemotherapy (NAC) at our institution.

Materials and Methods

Pts diagnosed with stage I to III TNBC from 2000 through 2018 who received NAC were included in this retrospective study. pCR was considered as absence of residual invasive cancer in the breast and lymph nodes after NAC. Association of race with pCR and survival outcomes were evaluated using logistic and Cox regression models, respectively. Multivariate models were used to evaluate the association between race and pCR or survival while controlling for relevant confounders including age, body mass index (BMI), insurance status, comorbidities, tumor stage, grade, and time from diagnosis to chemotherapy or surgery. Analysis was conducted using SAS version 9.4 (SAS Institute) at a significance level of .05.

Results

Included in the analysis were 186 pts (126 NHW, 67.7%; 50 NHB, 26.9%; 10 other, 5.4%). NHB pts had higher mean BMI at baseline (32.93 vs 27.45 kg/m2; P <.001), with fewer NHB pts having private insurance than NHW pts (46.0% vs 71.4%; P = .013). No significant association of race with other variables was observed. Pts with pCR were younger at diagnosis (48 vs 52 years; P = .019). Advanced age, higher tumor stage, and longer time from diagnosis to surgery were associated with worse RFS and OS (P <.05). On multivariate analysis, there were no significant associations between race and pCR, RFS, or OS, with similar pCR noted between different races (Table).

TABLE.Association of Race With pCR and Survival Outcomes on Multivariate

Analysis

TABLE.Association of Race With pCR and Survival Outcomes on Multivariate

Analysis

Conclusions

Our study suggests similar outcomes between races for TNBC treated at a single academic center. Further studies comparing molecular characteristics of TNBC from different races are warranted.

Articles in this issue

1 The Tolerance of CREATE-X Capecitabine Dosing in a United States TNBC Patient Population
1 The Tolerance of CREATE-X Capecitabine Dosing in a United States TNBC Patient Population
6 Survival Benefit of Eribulin, But Not Capecitabine, for Metastatic Breast Cancer Is Associated With Baseline Absolute Lymphocyte Count in Peripheral Blood
6 Survival Benefit of Eribulin, But Not Capecitabine, for Metastatic Breast Cancer Is Associated With Baseline Absolute Lymphocyte Count in Peripheral Blood
7 Evaluation of the 21-Gene Recurrence Score (RS) Assay Results Following Successful Intraoperative Radiation Therapy (IORT) Treatment of Patients With Early-Stage Breast Cancer
7 Evaluation of the 21-Gene Recurrence Score (RS) Assay Results Following Successful Intraoperative Radiation Therapy (IORT) Treatment of Patients With Early-Stage Breast Cancer
8 Concordance of Tumor Response with Eribulin Use in Real-World Clinical Practice
8 Concordance of Tumor Response with Eribulin Use in Real-World Clinical Practice
13 Real-world Treatment Patterns and Tumor Response of Palbociclib Plus an Aromatase Inhibitor for Metastatic Breast Cancer: Flatiron Database Analysis
13 Real-world Treatment Patterns and Tumor Response of Palbociclib Plus an Aromatase Inhibitor for Metastatic Breast Cancer: Flatiron Database Analysis
14 Real-World (RW) Treatment Patterns and Clinical Effectiveness of Palbociclib (PAL) Plus an Aromatase Inhibitor (AI) as First-Line Therapy in Advanced/ Metastatic Breast Cancer (A/MBC): Analysis From Syapse Learning Health Network
14 Real-World (RW) Treatment Patterns and Clinical Effectiveness of Palbociclib (PAL) Plus an Aromatase Inhibitor (AI) as First-Line Therapy in Advanced/ Metastatic Breast Cancer (A/MBC): Analysis From Syapse Learning Health Network
25 A Retrospective Cohort Study of Demographic, Clinical, and Treatment Characteristics of Patients With Metastatic Breast Cancer Who Have Received PARP Inhibitors
25 A Retrospective Cohort Study of Demographic, Clinical, and Treatment Characteristics of Patients With Metastatic Breast Cancer Who Have Received PARP Inhibitors
28 Primary Outcome Analysis of Invasive Disease-Free Survival for monarchE: Abemaciclib Plus Adjuvant Endocrine Therapy for High-Risk Early Breast Cancer
28 Primary Outcome Analysis of Invasive Disease-Free Survival for monarchE: Abemaciclib Plus Adjuvant Endocrine Therapy for High-Risk Early Breast Cancer
30 Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Early- Stage Breast Cancer (ESBC) Receiving Docetaxel and Cyclophosphamide
30 Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Early- Stage Breast Cancer (ESBC) Receiving Docetaxel and Cyclophosphamide
35 Decreased Epithelial Mesenchymal Transition Process After AGTR-1 Gene Edition By Crispr/Cas9, Losartan, and PARP Inhibitor Treatment In Breast Cancer Cell Line
35 Decreased Epithelial Mesenchymal Transition Process After AGTR-1 Gene Edition By Crispr/Cas9, Losartan, and PARP Inhibitor Treatment In Breast Cancer Cell Line
37 Treatment Outcomes Using Neoadjuvant Chemotherapy for HER2-Positive Breast Cancer in African American and Hispanic Women
37 Treatment Outcomes Using Neoadjuvant Chemotherapy for HER2-Positive Breast Cancer in African American and Hispanic Women
42 The United States Retrospective Claims Database Analysis of Demographic, Clinical, and Treatment Characteristics of Metastatic Breast Cancer Patients receiving Olaparib
42 The United States Retrospective Claims Database Analysis of Demographic, Clinical, and Treatment Characteristics of Metastatic Breast Cancer Patients receiving Olaparib
43 Lobular Cancer Responsiveness to Chemotherapy Is Equivalent to That of Ductal Cancer With Similar Genomic Profiles: An NCDB Analysis
43 Lobular Cancer Responsiveness to Chemotherapy Is Equivalent to That of Ductal Cancer With Similar Genomic Profiles: An NCDB Analysis
44 Drivers of Oncologist Treatment Selection in HR+/HER2- Metastatic Breast Cancer
44 Drivers of Oncologist Treatment Selection in HR+/HER2- Metastatic Breast Cancer
45 Neoadjuvant Chemotherapy Use in Elderly Patients
45 Neoadjuvant Chemotherapy Use in Elderly Patients
Related Content